LeonaBio, Inc. (LONA) is a pre-revenue clinical-stage biopharmaceutical company. As of March 31, 2026, total assets are $71.6M against total liabilities of $22.3M, yielding GAAP book equity of $49.3M. Under a liquidation lens, recoverable asset value is materially lower than book. Cash and restricted cash total approximately $33.5M (100% recovery). Short-term investments of $34.8M are in available-for-sale debt securities, recoverable near par assuming liquid markets. Prepaid and other current assets of $1.5M are largely non-recoverable. PP&E gross of $5.7M less $4.5M accumulated depreciation gives net book of $1.2M; at a 50-60% haircut on net book, recoverable value is roughly $0.6-0.7M. Intangibles and in-process IP (including the December 2025 lasofoxifene in-license) carry zero liquidation value. Operating ROU asset of $0.5M is worthless on wind-up. Estimated liquidation asset pool: approximately $68-69M. Liability stack at face value: current liabilities of $6.7M (accounts payable $1.8M, accrued liabilities $4.4M, current operating lease $0.5M); noncurrent liabilities of $15.6M, including warrant liability implied by the $16.3M FairValueAdjustmentOfWarrants charge (the December 2025 PIPE-related warrants represent a significant non-debt liability claim that does not extinguish on liquidation). OtherLiabilitiesNoncurrent of $1.2M and noncurrent lease of $0.2M also remain at face. The warrant liability is the dominant uncertainty: the $16.3M mark-to-market charge in Q1 2026 alone indicates the warrants have substantial fair value, and on liquidation the warrant holders would have contractual claims against proceeds. Remaining operating lease commitments through 2027 total $0.7M gross and do not extinguish on wind-up. Net recovery to equity under liquidation appears modestly positive in the range of $25-49M depending on warrant fair value treatment, consistent with MFFAIS CLV/LLV/OLV of $26.0M. The company acknowledges in its risk factors that its market cap has at times been below aggregate cash and investments, inviting activist pressure for liquidation. The filing covers Q1 2026 (period ending March 31, 2026); the prior filing was the 10-K for the year ending December 31, 2025. Cash declined by $36.4M in Q1 2026, driven by $20.9M in operating cash burn and $15.5M net investment in available-for-sale securities. With $33.5M in unrestricted cash plus $34.8M in short-term investments equaling approximately $68M in liquid assets, the company has roughly 6-9 quarters of runway at current burn before reaching distress, absent further capital raises. The filing does not separately tag the warrant liability as a distinct balance sheet line in XBRL; it is referenced via the FairValueAdjustmentOfWarrants income statement tag and discussed in MD&A as a material non-cash item.
▼ Community Notes